Loading…
Limited Efficacy of Thalidomide in the Treatment of Febrile Attacks of the Hyper-IgD and Periodic Fever Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Hyper-IgD and periodic fever syndrome (HIDS) is an autosomal recessive disorder featured by recurrent febrile attacks. Previous unpublished experience (J. van der Meer and R. Powell) suggested that thalidomide may prevent febrile attacks. Six HIDS patients (5 male and 1 female) who had at least one...
Saved in:
Published in: | The Journal of pharmacology and experimental therapeutics 2001-09, Vol.298 (3), p.1221 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Hyper-IgD and periodic fever syndrome (HIDS) is an autosomal recessive disorder featured by recurrent febrile attacks. Previous
unpublished experience (J. van der Meer and R. Powell) suggested that thalidomide may prevent febrile attacks. Six HIDS patients
(5 male and 1 female) who had at least one febrile attack every 6 weeks, entered a randomized, double-blind, placebo-controlled
crossover trial to explore the efficacy of a daily 200-mg thalidomide dose in the treatment of recurrent febrile attacks of
HIDS. The patients received either thalidomide, 200-mg daily, or placebo for 16 weeks, followed by a 4-week washout period
and another 16-week treatment (crossover) with either thalidomide or placebo. Patients completed a weekly diary card noting
attacks and side effects. During the study, C-reactive protein (CRP), serum amyloid A (SAA), interleukin (IL)-6, tumor necrosis
factor (TNF)-α, IL-1 receptor antagonist, soluble TNF receptor p55 and p75, and lipopolysaccharide-stimulated IL-1β and TNF-α
production were measured at six different points, whereas urine neopterin levels were measured weekly. During the active treatment
with thalidomide, there were 10 attacks compared with 13 attacks with placebo. Thalidomide resulted in a nonsignificant decrease
of CRP and SAA, but the concentrations of other inflammatory mediators, including urine neopterin, remained unchanged. One
patient developed sensory polyneuropathy, but this resolved when thalidomide administration was stopped. The effect of thalidomide
in HIDS is limited to a decrease in acute phase protein synthesis without an effect on the attack rate. |
---|---|
ISSN: | 0022-3565 1521-0103 |